Fig. 1 Urea-based Aβ-SDS–PAGE/immunoblot (A) and conventional SDS–PAGE (B) of CSF (lane 1–4,6) and synthetic Aβ-peptides 1–37, 1–38, 1–39, 1–40, 1–42 (lane.

Slides:

Advertisements

Similar presentations

Visuospatial executive function in Turner syndrome: functional MRI and neurocognitive findings by Sarah J. Hart, Marsha L. Davenport, Stephen R. Hooper,

Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

From: An open day in the metric space

FIG. 1. The concentration dependent effect of DCPA on [Ca2+]i in anti-CD3 stimulated Jurkat cells. Jurkat cells were loaded with.

Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.

Figure 2. Chronic kidney disease risk tool application.

Fig. 1 Argumentation flow chart: Steps 2–4 are repeated for each match in the search results, until all have been classified as good, bad or undecided.

Figure 1 A screenshot of the MovieMaker home page showing the different animation options. From: MovieMaker: a web server for rapid rendering of protein.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

Figure 1 Individual Lifted from Group Photograph

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Fast chromatin immunoprecipitation assay

Figure 4 RNA stem–loop structure of the psbD 5′ region

From: Detection of Bacteriuria by Canine Olfaction

Fig. 1. The required sample sizes nPPV and nNPV versus the sample allocation fraction P for the case study. From: Sample size for.

From: Intention, Interpretation, and Contemporary Visual Art

Figure 1. Publication channels used by scholars at the faculty of Arts, 2006–2013. From: Accountability in context: effects of research evaluation systems.

Figure 3: Full-body skeletal scintigraphy.

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

Figure 1. Study population diagram

FIGURE 1. Estimated instantaneous fault detection rate

Fig. 5 Detailed classifier results for tweets (a) J48, (b) SVM, and (c) NB From: A sentiment analysis system for social media using machine learning techniques:

Fig. 1 Languages used for SA

Figure 1. HR (95% CI) of death from dementia associated with weight or BMI in middle age and in old age. From: Adiposity in middle and old age and risk.

Figure 4. Influence of Clerk Ideology on Justice Voting.

Figure 1 Experimental workflow and predictive modelling

Figure 1 Flowchart of our CIS cohort considering patients (A) and eyes (B) as statistical unit. Unless provided in the caption above, the following copyright.

Fig. 1. Axial, coronal, and sagittal views of post hoc results (mean gFA) demonstrating significant differences ... Fig. 1. Axial, coronal, and sagittal.

Figure 1 Schematic representation of the experimental design.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

bDMARD: biologic DMARD.

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

Figure 1. Profiles of the top 50 mRNA probes of the first gene signature identified in the South African cohort. ... Figure 1. Profiles of the top 50 mRNA.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient disposition

Fig. 1 A network representation of top 100 co-occurring terms

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Fig. 1 Statistics of the main characters’ dialogues.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression Immunoprecipitation of CD147 from RBL.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1 ABCDE of primary prevention.2

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Presentation transcript:

Fig. 1 Urea-based Aβ-SDS–PAGE/immunoblot (A) and conventional SDS–PAGE (B) of CSF (lane 1–4,6) and synthetic Aβ-peptides 1–37, 1–38, 1–39, 1–40, 1–42 (lane 5). Ten microlitres of an unconcentrated CSF pool of seven NDC (lane 1), Alzheimer's disease (lane 2), PDD (lane 3) and DLB (lane 4) patients were applied. 1E8 immunoprecipitated CSF pool of seven DLB patients was applied to lane 6. Quantifications have been obtained from individual blots of each patient. From: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain. 2006;129(5):1177-1187. doi:10.1093/brain/awl063 Brain | © The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Fig. 2 One- and two-dimensional Aβ-SDS–PAGE/immunoblot of 1E8 immunoprecipitated CSF pool of seven DLB patients: one-dimensional separation in the urea-based Aβ-SDS–PAGE/immunoblot (A) in comparison with urea-based Aβ-SDS–PAGE/immunoblot after conventional SDS–PAGE [non-urea/urea SDS–PAGE (B)] and electrofocussing by IPG [Aβ-IPG-2D-PAGE (C)], respectively. From: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain. 2006;129(5):1177-1187. doi:10.1093/brain/awl063 Brain | © The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Fig. 3 Mean and 95% confidence interval (CI) of absolute Aβ1–37 and Aβ1–42 levels for each diagnostic group. Only significant differences are indicated within the figure. From: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain. 2006;129(5):1177-1187. doi:10.1093/brain/awl063 Brain | © The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Fig. 4 Mean and 95% confidence interval (CI) of the Aβ1–42 : Aβ1–37 ratio for each diagnostic group. Only significant differences are indicated within the figure. From: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain. 2006;129(5):1177-1187. doi:10.1093/brain/awl063 Brain | © The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Fig. 5 Mean and 95% confidence interval (CI) of the relative abundance of Aβ1–40<sup>*</sup> (Aβ 1–40<sup>*</sup>%) for PDD and DLB. The difference between PDD and DLB was highly significant (P = 6.0 × 10<sup>−4</sup>). From: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain. 2006;129(5):1177-1187. doi:10.1093/brain/awl063 Brain | © The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org